Dactolisib (BEZ235)

For research use only.

Catalog No.S1009 Synonyms: NVP-BEZ235

297 publications

Dactolisib (BEZ235) Chemical Structure

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Dactolisib (BEZ235) has been cited by 297 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3TopBP1-ER cell. Dactolisib induces autophagy and suppresses HIV-1 replication. Phase 2.
Targets
p110α [1]
(Cell-free assay)		 p110γ [1]
(Cell-free assay)		 mTOR (p70S6K) [1]
(Cell-free assay)		 p110δ [1]
(Cell-free assay)		 ATR [8]
(3T3TopBP1-ER cells)
4 nM 5 nM 6 nM 7 nM 21 nM
In vitro

BEZ235 significantly reduces the phosphorylation levels of the mTOR activated kinase p70S6K. BEZ235 results in a reduction of S235/S236P-RPS6 levels with IC50 of 6.5 nM. The activity of BEZ235 against mTOR is determined using a biochemical mTOR K-LISA assay with IC50 of 20.7 nM. BEZ235 shows slightly lower activity against its β paralogue with IC50 of 75 nM. The PI3K/Akt/mTOR pathway is often constitutively activated in human tumor cells. BEZ235 blocks PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. Both PTEN-null cell lines PC3M and U87MG show a dose-dependent reduction in cell proliferation when treated with increasing concentrations of BEZ235 with an average GI50 of 10-12 nM. [1] BEZ235 is an mTORC1/2 catalytic inhibitor. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Trypanosoma brucei brucei M4DRRmFvfGmvaXPyc4Jq[WxiQYPzZZk> NELzPHYyQCCq M3WxcGROW09? NGTxWFRCdnSrdIL5dIFvd3OxbXHsJIFkfGm4aYT5JJdqfGhiRVO1NEBw\iByLkCwNlUh|ryP MlriNlQ5ODV7NE[=
MCF7 M2\tNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;jNE4xOS1zMECg{txO NVXCNWlPPDhiaB?= MY\EUXNQ MVLJR|UxRTBwN{Og{txO NFi5TWwzOzh5MUmwOC=>
HCT116 NWrGRoZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPwNE4xOS1zMECg{txO NUHScVQ3PDhiaB?= NEPlUIxFVVOR M3LxdmlEPTB;MT6xOkDPxE1? MUWyN|g4OTlyNB?=
U87MG NVS4TW5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGq1eWIxNjBzLUGwNEDPxE1? NE\DZ4s1QCCq M{XuVWROW09? M33ucGlEPTB;MT6zNkDPxE1? MnXqNlM5PzF7MES=
HBC4 Mk\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\sXFAvODFvMUCwJO69VQ>? NX;UTo1tPDhiaB?= M1zncWxw\yCJSUWwQU05NjZzIF2= M{n4d|IzOzN4MkS2
BSY1 M4jHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DqTlAvODFvMUCwJO69VQ>? Ml3sOFghcA>? MWLMc4chT0l3ME2tPE41QCCP Ml;NNlI{OzZ{NE[=
HBC5 NFzJfoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn1NE4xOS1zMECg{txO M3\WPVQ5KGh? NELSOpRNd2diR1m1NF0uPy56NzDN MXOyNlM{PjJ2Nh?=
MCF7 NWDne5hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13VPVAvODFvMUCwJO69VQ>? MWC0PEBp NXW2PVhIVG:pIFfJOVA:NThwMU[gUS=> MnTPNlI{OzZ{NE[=
MDA-MB-231 NX3aSGs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUewMlAyNTFyMDFOwG0> MorlOFghcA>? MmPFUI9oKEeLNUC9MVgvODliTR?= MmfwNlI{OzZ{NE[=
U251 M4DqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXQe3IxNjBzLUGwNEDPxE1? MUG0PEBp NH[zcppNd2diR1m1NF0uPy54NjDN MUCyNlM{PjJ2Nh?=
SF268 NIDLZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\YR|AvODFvMUCwJO69VQ>? NF;vVI41QCCq MoLkUI9oKEeLNUC9MVcvQTJiTR?= NXXDOJYxOjJ|M{[yOFY>
SF295 M3\1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPWXHFUOC5yMT2xNFAh|ryP MVy0PEBp MmG0UI9oKEeLNUC9MVgvOzFiTR?= NW\mVZJVOjJ|M{[yOFY>
SF539 NFHucJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHyNE4xOS1zMECg{txO Mnz2OFghcA>? NELxXHlNd2diR1m1NF0uQC53OTDN NETwVI8zOjN|NkK0Oi=>
SNB75 NVTBR2dFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[wUVAvODFvMUCwJO69VQ>? M{LCRVQ5KGh? M4jrXWxw\yCJSUWwQU05NjV6IF2= MlnaNlI{OzZ{NE[=
SNB78 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYiwMlAyNTFyMDFOwG0> NGD6[VM1QCCq MUDMc4chT0l3ME2tPE43PSCP NEXTcVUzOjN|NkK0Oi=>
HCC2998 NI\VSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHniZ5IxNjBzLUGwNEDPxE1? MWG0PEBp MWHMc4chT0l3ME2tPE4xPSCP M4G5NlIzOzN4MkS2
KM12 NEG3VpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTDNE4xOS1zMECg{txO MkXBOFghcA>? NGHvVI5Nd2diR1m1NF0uPy53NDDN M4DQWVIzOzN4MkS2
HT-29 NGTlbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKwMlAyNTFyMDFOwG0> M3vJ[|Q5KGh? M4TJZ2xw\yCJSUWwQU04Njd3IF2= MXmyNlM{PjJ2Nh?=
HCT15 NYTiVZB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmwMlAyNTFyMDFOwG0> M4jNcVQ5KGh? NWrtOJp5VG:pIFfJOVA:NThwMEOgUS=> MnjBNlI{OzZ{NE[=
HCT116 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnxNE4xOS1zMECg{txO NU\sbJl4PDhiaB?= NUK1N|RWVG:pIFfJOVA:NTdwNkGgUS=> NXfaTmxWOjJ|M{[yOFY>
NCI-H23 NILnR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfOWplYOC5yMT2xNFAh|ryP NV7tfGNmPDhiaB?= NV63Rmg4VG:pIFfJOVA:NTdwNkSgUS=> M1[4VFIzOzN4MkS2
NCI-H226 NFqzUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPHOIcxNjBzLUGwNEDPxE1? M2W3e|Q5KGh? M17UPGxw\yCJSUWwQU05NjR2IF2= NVXuPJVuOjJ|M{[yOFY>
NCI-H522 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH2eIUxNjBzLUGwNEDPxE1? NVr6SJRvPDhiaB?= Mn;mUI9oKEeLNUC9MVgvPDViTR?= M3\ydVIzOzN4MkS2
NCI-H438 M4rkZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m3dFAvODFvMUCwJO69VQ>? M2TVWVQ5KGh? M2LSZmxw\yCJSUWwQU05NjFzIF2= MkjRNlI{OzZ{NE[=
A549 NGXT[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HFdVAvODFvMUCwJO69VQ>? NXi0fHlkPDhiaB?= NHXvbHpNd2diR1m1NF0uQC5yNzDN MmrsNlI{OzZ{NE[=
DMS273 NX3pNmxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCwMlAyNTFyMDFOwG0> NHnoT|I1QCCq MWfMc4chT0l3ME2tO{45OCCP MWmyNlM{PjJ2Nh?=
DMS114 Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrpNE4xOS1zMECg{txO NFjS[IM1QCCq MVPMc4chT0l3ME2tPE4{QSCP NWe4eXFuOjJ|M{[yOFY>
LOXIMVI MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDC[ngxNjBzLUGwNEDPxE1? NInBV4c1QCCq NG\WfWFNd2diR1m1NF0uQC54NjDN M1rCTVIzOzN4MkS2
OVCAR3 NUnhZoQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\ZV2wxNjBzLUGwNEDPxE1? M1TBRlQ5KGh? M4K4b2xw\yCJSUWwQU05NjF5IF2= NUPMdpF7OjJ|M{[yOFY>
OVCAR4 Mn7uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfaRVlHOC5yMT2xNFAh|ryP M4PQT|Q5KGh? MonmUI9oKEeLNUC9MVgvPThiTR?= MoTGNlI{OzZ{NE[=
OVCAR5 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHCb|R7OC5yMT2xNFAh|ryP NVPXfFg4PDhiaB?= M1y1OWxw\yCJSUWwQU04NjV5IF2= NF21T28zOjN|NkK0Oi=>
OVCAR8 MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSwc4Q5OC5yMT2xNFAh|ryP NY\MTpNSPDhiaB?= MnjmUI9oKEeLNUC9MVcvQDRiTR?= MXmyNlM{PjJ2Nh?=
SKOV3 NGHxPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnToNE4xOS1zMECg{txO M2fn[lQ5KGh? NEHT[HpNd2diR1m1NF0uQC52MTDN MmLsNlI{OzZ{NE[=
RXF631L MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ftTVAvODFvMUCwJO69VQ>? NEW0UGc1QCCq MmP0UI9oKEeLNUC9MVgvOjFiTR?= Ml2wNlI{OzZ{NE[=
ACHN MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLsNE4xOS1zMECg{txO NFf6NI41QCCq NXHCOZA4VG:pIFfJOVA:NTdwOUWgUS=> M1XKO|IzOzN4MkS2
St-4 NYjaSJpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\BRWMxNjBzLUGwNEDPxE1? M36xO|Q5KGh? NV[wbphuVG:pIFfJOVA:NTdwNEegUS=> NEXP[lUzOjN|NkK0Oi=>
MKN1 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUewMlAyNTFyMDFOwG0> M4C5S|Q5KGh? NWLEV482VG:pIFfJOVA:NThwNEGgUS=> MYeyNlM{PjJ2Nh?=
MKN7 NF[4NZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXKdHAxNjBzLUGwNEDPxE1? MkLaOFghcA>? M2nFdmxw\yCJSUWwQU04NjZ6IF2= NVTkWGNKOjJ|M{[yOFY>
MKN28 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnDNE4xOS1zMECg{txO MoDBOFghcA>? NWD3enRXVG:pIFfJOVA:NTdwMEegUS=> NXm4UIg3OjJ|M{[yOFY>
MKN45 MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOwMlAyNTFyMDFOwG0> M1H1O|Q5KGh? MmHjUI9oKEeLNUC9MVgvOzRiTR?= M1HzSFIzOzN4MkS2
MKN74 M2TK[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zkclAvODFvMUCwJO69VQ>? NXvUUnNEPDhiaB?= M4nhR2xw\yCJSUWwQU04NjR{IF2= M4LSNlIzOzN4MkS2
DU145 NX7rV|dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMlAyNTFyMDFOwG0> NHf6e4Q1QCCq MWrMc4chT0l3ME2tPE4yPiCP MlrJNlI{OzZ{NE[=
PC3 NETab3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M321flAvODFvMUCwJO69VQ>? M{Xr[|Q5KGh? M1rG[Gxw\yCJSUWwQU05NjZ4IF2= MX6yNlM{PjJ2Nh?=
Trypanosoma brucei brucei NIX1NWpHfW6ldHnvckBCe3OjeR?= NEW0eHczODBibl2= NG\wZVIyOiCq MWfEUXNQ MW\E[YNz\WG|ZTDpckBxcG:|cHjveIllgWxiaX7vd4l1d2xicHjvd5Bp[XSnIHzleoVt M3HIdFI1QDB3OUS2
Trypanosoma brucei brucei NWfnbmJZTnWwY4Tpc44hSXO|YYm= NYHsUIpmOThiaB?= MXfEUXNQ M3LMd2lvcGmkaYTpc44hd2ZicnXj[ZB1d3JvbXXkbYF1\WRiZX7kc4N6fG:|aYOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5idILhcpNn\XK{aX6geZB1[Wun M2\4O|I1QDB3OUS2
Trypanosoma brucei brucei NW[3UIxpTnWwY4Tpc44hSXO|YYm= NGOzR|EzODBibl2= MlHxNVIhcA>? NVy4botHTE2VTx?= NHjpT4tG\m[nY4Sgc44he3CqaX7nc416dGWrbjDs[ZZmdA>? NVW2NWZEOjR6MEW5OFY>
Trypanosoma brucei brucei NXz3RZU{TnWwY4Tpc44hSXO|YYm= NHXsbmQzODBibl2= NHqzXYcyOiCq NHHpcG5FVVOR M3rkUmVn\mWldDDvckBxcG:|cHjheIllgWylaH;sbY5mKGyndnXs NWi2TpIxOjR6MEW5OFY>
UM-UC-3 NUjZRWR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPCUXVsUUN3ME2zNVUheE1? NWXRfldMW0GQR1XS
SBC-1 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXqXpBIUUN3ME23OFIheE1? NYq1ZWl4W0GQR1XS
MKN1 MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfnTWM2OD1{Lkigcm0> MlHlV2FPT0WU
NCI-H720 M4jke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fPcGlEPTB;Mz61O{BvVQ>? NUnkXm06W0GQR1XS
BFTC-909 NFXuU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;QV29KSzVyPUOuO|Ehdk1? Mn3oV2FPT0WU
BPH-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW3e3pKSzVyPUSuO|Yhdk1? NIfPT4FUSU6JRWK=
PC-3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nMN2lEPTB;NT6wPUBvVQ>? MlHWV2FPT0WU
AN3-CA NXnJOlZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPqTWM2OD13LkW2JI5O MlTYV2FPT0WU
HN MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHDblZKSzVyPUWuPVYhdk1? NGHUTmVUSU6JRWK=
HCC2218 Mnj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoiyTWM2OD14Lk[xJI5O MWrTRW5ITVJ?
KP-4 MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDuTWM2OD15IH7N MXfTRW5ITVJ?
LU-139 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDlWZZKSzVyPUeuO|chdk1? MmLnV2FPT0WU
ETK-1 NI\tR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zCOGlEPTB;Nz64PEBvVQ>? NILiWYZUSU6JRWK=
Ramos-2G6-4C10 NG\m[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnaR4JKSzVyPUiuOFkhdk1? M1TJ[XNCVkeHUh?=
MHH-PREB-1 NUW3d5VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[xTWM2OD17LkGyJI5O MXHTRW5ITVJ?
DU-4475 NGTUXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37ESmlEPTB;OT60OEBvVQ>? MlzuV2FPT0WU
NCI-H1666 NWjTXnBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\TbHBqUUN3ME25MlcyKG6P MlfUV2FPT0WU
CAMA-1 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTlwODDuUS=> M2nRVXNCVkeHUh?=
TYK-nu M4rEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDCWlJRUUN3ME25Mlk1KG6P MYLTRW5ITVJ?
MFE-280 NVnkUGhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvDfYZtUUN3ME25Mlk6KG6P MkH5V2FPT0WU
A549 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\CN2lEPTB;MUCuNVQhdk1? M37Yc3NCVkeHUh?=
769-P MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFuxUWpKSzVyPUGwMlQ1KG6P NIjKT3ZUSU6JRWK=
L-363 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLUTWM2OD1zMD62PUBvVQ>? NWP3c3dOW0GQR1XS
ES8 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[1TWM2OD1zMD65JI5O MWTTRW5ITVJ?
PA-1 MljvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTPfFBOUUN3ME2xNU45OiCwTR?= MkDaV2FPT0WU
Mewo NYToZ3RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XP[GlEPTB;MUGuPVkhdk1? NXHhR25zW0GQR1XS
HSC-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjuTWM2OD1zMj6yNUBvVQ>? MWTTRW5ITVJ?
H4 NWTFW2gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTQb3JKSzVyPUGyMlY4KG6P NV:wSWJ2W0GQR1XS
BB65-RCC MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjXTWM2OD1zMj63NkBvVQ>? MmDVV2FPT0WU
NCI-H1793 M2S2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXTeXpKSzVyPUGyMlgzKG6P MXrTRW5ITVJ?
KARPAS-45 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ueW9oUUN3ME2xN{42OSCwTR?= MkTYV2FPT0WU
GCT NHHydFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfaVFFjUUN3ME2xN{43QCCwTR?= M2LDc3NCVkeHUh?=
EoL-1 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES1U5RKSzVyPUGzMlk{KG6P NVfrfYxNW0GQR1XS
LB2241-RCC MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDSWYhZUUN3ME2xOE4xOSCwTR?= MXfTRW5ITVJ?
ES5 MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEn5TnlKSzVyPUG0Mlc1KG6P MUDTRW5ITVJ?
LOXIMVI MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjSVZlKSzVyPUG0Mlk6KG6P MWfTRW5ITVJ?
COR-L105 NUW2fHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXQUpBKSzVyPUG1MlA1KG6P NIH2fYtUSU6JRWK=
P12-ICHIKAWA NYPo[G43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rpbGlEPTB;MUWuNUBvVQ>? NXrSbWFPW0GQR1XS
CHL-1 NGmwPVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL2Vlk6UUN3ME2xOU41PSCwTR?= M{fqPXNCVkeHUh?=
VMRC-RCZ NVnKRpVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTKTWM2OD1zNT62N{BvVQ>? MlLtV2FPT0WU
HH MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF3Lkegcm0> MnrjV2FPT0WU
NUGC-3 M{LnUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF4LkO0JI5O NEHpWldUSU6JRWK=
EGI-1 MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ftdmlEPTB;MU[uOFMhdk1? MlrIV2FPT0WU
OS-RC-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF4LkS3JI5O MlvWV2FPT0WU
MOLT-16 NFnyVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTF5LkG1JI5O MVrTRW5ITVJ?
NCI-H209 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrYbJNKSzVyPUG3MlI6KG6P NGL5ZopUSU6JRWK=
697 M2HYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rwcGlEPTB;MUeuOFMhdk1? MmDmV2FPT0WU
D-56MG NH\SUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjQTWM2OD1zNz62PUBvVQ>? MXnTRW5ITVJ?
VA-ES-BJ MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofwTWM2OD1zNz64N{BvVQ>? M2HtR3NCVkeHUh?=
EW-16 M3jhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe3XW5VUUN3ME2xPE4xPCCwTR?= NVrHRo1yW0GQR1XS
HGC-27 NXHoW3RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XJTWlEPTB;MUiuNFYhdk1? MmDqV2FPT0WU
ES7 Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXjZnVKSzVyPUG4MlA6KG6P NIXINoFUSU6JRWK=
HuH-7 NHXzflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu1TWM2OD1zOD60JI5O MnjWV2FPT0WU
BCPAP NIm5OFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\zenh[UUN3ME2xPE43PSCwTR?= NXPMVlhxW0GQR1XS
SW1710 NW\RUWkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HDZmlEPTB;MUiuO|Ihdk1? M4TQOHNCVkeHUh?=
IST-MEL1 NV7xR4xWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTVZ2cyUUN3ME2xPE44PyCwTR?= NUTKVJVEW0GQR1XS
SF295 NGDGfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF6LkmzJI5O NX7aPGNWW0GQR1XS
RPMI-7951 NHvT[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWO5OoZIUUN3ME2xPU4zQCCwTR?= M2[zd3NCVkeHUh?=
SF126 M4K2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rydGlEPTB;MUmuOFEhdk1? NGHkUWpUSU6JRWK=
GAMG MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF7LkS4JI5O M2f4bnNCVkeHUh?=
KNS-81-FD M1S3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LCW2lEPTB;MUmuOVQhdk1? MYLTRW5ITVJ?
RT-112 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y4ZmlEPTB;MUmuOlYhdk1? NFvBU|FUSU6JRWK=
DEL NHfPfHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWSyOnJMUUN3ME2yNE41QSCwTR?= MWHTRW5ITVJ?
CGTH-W-1 NEDsUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJyLk[zJI5O MV7TRW5ITVJ?
HOS MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfiTGY2UUN3ME2yNU4xPiCwTR?= M3PJW3NCVkeHUh?=
ES4 MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPKVmdLUUN3ME2yNU4xQCCwTR?= NW\IXI15W0GQR1XS
RXF393 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlO4TWM2OD1{MT60OUBvVQ>? MVrTRW5ITVJ?
NCI-H2030 NEP0XotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnQclVKSzVyPUKxMlUzKG6P NXTZbXQ4W0GQR1XS
YH-13 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLJbZVKSzVyPUKxMlg5KG6P MX7TRW5ITVJ?
HT-1080 M2Hobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnib4NHUUN3ME2yNU46OyCwTR?= M3\wV3NCVkeHUh?=
NCI-SNU-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHuOXk2UUN3ME2yNU46PSCwTR?= MXfTRW5ITVJ?
G-402 M3GwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ{LkG2JI5O NInvdYVUSU6JRWK=
786-0 M2rhTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XmbGlEPTB;MkKuNlkhdk1? NXrN[XNuW0GQR1XS
ME-180 NUDjcXdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XEXGlEPTB;MkKuOFMhdk1? NEPXcFNUSU6JRWK=
NB69 MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fBRWlEPTB;MkKuOVMhdk1? MmTJV2FPT0WU
J-RT3-T3-5 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLvTWM2OD1{Mj65OkBvVQ>? M3uwSXNCVkeHUh?=
TGBC1TKB MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXwSZFMUUN3ME2yN{4xPSCwTR?= NIXEdJNUSU6JRWK=
SW780 NFv4PHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETkclZKSzVyPUKzMlE{KG6P NETCN|BUSU6JRWK=
MG-63 NHvi[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7pblN2UUN3ME2yN{41PSCwTR?= M{LQSnNCVkeHUh?=
BV-173 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD0TWM2OD1{Mz64O{BvVQ>? NFzjRW9USU6JRWK=
CAL-51 M{POfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\0T2lEPTB;MkOuPFkhdk1? MnvnV2FPT0WU
A375 M2HQbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r3NmlEPTB;MkOuPVMhdk1? NFzVc3NUSU6JRWK=
MEL-HO M3jpVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\oTppKSzVyPUK0MlA1KG6P NIe4U2ZUSU6JRWK=
EFO-27 NFLEOpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvTTWM2OD1{ND6zN{BvVQ>? MWDTRW5ITVJ?
Hs-578-T M3fBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP5ZYhKSzVyPUK0MlU5KG6P MYLTRW5ITVJ?
NBsusSR NHLafoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzGc5NKSzVyPUK0MlYhdk1? NFrsR2NUSU6JRWK=
CTB-1 MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj4d|JKSzVyPUK0MlY4KG6P NVXLU4pGW0GQR1XS
FTC-133 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\aOXRKSzVyPUK1MlEhdk1? M33ueHNCVkeHUh?=
MOLT-4 M3fwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnETWM2OD1{NT6xNkBvVQ>? NUC2VY81W0GQR1XS
HO-1-N-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJ3LkG1JI5O MWTTRW5ITVJ?
ES3 NHvxPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv3TWM2OD1{NT6yNkBvVQ>? NYrHc3JMW0GQR1XS
TI-73 NIr2T2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ3LkK4JI5O M2XCZXNCVkeHUh?=
MPP-89 NInCSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETXfGlKSzVyPUK1MlMzKG6P M{PXb3NCVkeHUh?=
KYSE-150 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJ3Lki5JI5O MoHEV2FPT0WU
LXF-289 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M321[mlEPTB;Mk[uNFQhdk1? NF;CXplUSU6JRWK=
SK-LU-1 M2\ud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH3TWM2OD1{Nj6xO{BvVQ>? MmPSV2FPT0WU
HOP-92 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HEWWlEPTB;Mk[uOFghdk1? MnfCV2FPT0WU
HuO9 M4WyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;2Z3BYUUN3ME2yOk44PiCwTR?= NHvpcVdUSU6JRWK=
SW962 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXHNG14UUN3ME2yOk44PiCwTR?= NIjSSVhUSU6JRWK=
RS4-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rLb2lEPTB;Mk[uPVEhdk1? MVXTRW5ITVJ?
NCI-H292 M3HlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjSfYo{UUN3ME2yO{BvVQ>? NYXLWIs3W0GQR1XS
DB M2W3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ5LkO2JI5O M17s[HNCVkeHUh?=
SW1088 NYPFOXd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPOTWM2OD1{OD6yPUBvVQ>? NV;obZFDW0GQR1XS
A204 NHTsVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnTcXFKSzVyPUK4MlQ4KG6P MnrZV2FPT0WU
A3-KAW M1\JNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nh[2lEPTB;MkiuOlQhdk1? NIDIbI1USU6JRWK=
MV-4-11 NIfUOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqyTnNKSzVyPUK4Mlchdk1? MWHTRW5ITVJ?
ES1 NVr1SlE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJ6Lki0JI5O M4P6dHNCVkeHUh?=
ONS-76 NVf0T|h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\lNpRKSzVyPUK5MlA2KG6P MorwV2FPT0WU
D-263MG Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr5TWM2OD1{OT6zOUBvVQ>? MnnxV2FPT0WU
U-2-OS NEP5RlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzlN|dxUUN3ME2yPU42KG6P Mn3jV2FPT0WU
T98G MnW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH5TWM2OD1{OT64PEBvVQ>? NV7SZXVuW0GQR1XS
GI-ME-N M1HTOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPtU3JRUUN3ME2yPU46OSCwTR?= MVjTRW5ITVJ?
BHT-101 NXvvWo8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTCWlRKSzVyPUOwMlA2KG6P MmC4V2FPT0WU
NOS-1 NX3mUIhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\KVHZnUUN3ME2zNE4yOiCwTR?= NUfoT2lzW0GQR1XS
AsPC-1 NIPYUXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNyLkKgcm0> NF7QPFhUSU6JRWK=
QIMR-WIL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTNyLk[gcm0> M{TPVHNCVkeHUh?=
JVM-3 Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LTZmlEPTB;M{CuPFMhdk1? NH;1UllUSU6JRWK=
KU-19-19 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHKTWM2OD1|MT6xN{BvVQ>? M3LjSnNCVkeHUh?=
OVCAR-8 M4nsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PMOGlEPTB;M{GuNlYhdk1? NV7EdHkyW0GQR1XS
BEN MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTNzLk[zJI5O NFjvNm9USU6JRWK=
BE-13 M{H4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XZbGlEPTB;M{GuPFIhdk1? NFnRUHlUSU6JRWK=
EW-18 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfjcFVKSzVyPUOxMlg3KG6P M3HhWHNCVkeHUh?=
ECC10 M{nsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNzLkm1JI5O Mk[xV2FPT0WU
CTV-1 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LNOGlEPTB;M{KuPFIhdk1? Mk[4V2FPT0WU
COLO-800 NFXvfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjoPYRKSzVyPUOyMlkzKG6P MlTzV2FPT0WU
A2058 NIDwXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jQRWlEPTB;M{OuNlUhdk1? NYO0WJpnW0GQR1XS
VM-CUB-1 NHzGbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN|LkSzJI5O NXzETWVnW0GQR1XS
Ca9-22 M3;4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfVWmVKSzVyPUOzMlU2KG6P NIjzVolUSU6JRWK=
COLO-684 M1nJcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXueHFKSzVyPUOzMlU5KG6P MX3TRW5ITVJ?
RPMI-8226 MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTN|LkiyJI5O Mlr5V2FPT0WU
SK-NEP-1 NUTUVGlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13IV2lEPTB;M{SuNVUhdk1? NUDETYJoW0GQR1XS
Becker NYXQZXRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfrNYFKSzVyPUO0MlIyKG6P M3rhS3NCVkeHUh?=
NCI-H28 M132S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDKTWM2OD1|ND60OEBvVQ>? NVHZWHBGW0GQR1XS
CAL-120 NFX5eJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXiyeYQ{UUN3ME2zOE44OiCwTR?= NYfYWVJkW0GQR1XS
MDA-MB-157 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTN3LkSxJI5O NGT1eFJUSU6JRWK=
OVCAR-5 NHTwZ4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fBSmlEPTB;M{WuOFchdk1? Mly4V2FPT0WU
LAMA-84 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;Ke5hKSzVyPUO1Mlg4KG6P M1fwO3NCVkeHUh?=
CAKI-1 NVe2S5JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP4TWM2OD1|Nj60N{BvVQ>? MoLkV2FPT0WU
Daoy M3;WNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN4Lkegcm0> MoX3V2FPT0WU
CAL-62 NUnOOmNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTN4Lki2JI5O NV3Oe5ZTW0GQR1XS
8-MG-BA MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETCUmVKSzVyPUO3MlI2KG6P NYDjbmZVW0GQR1XS
8505C Mo\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTN5LkWxJI5O MnLhV2FPT0WU
LNCaP-Clone-FGC NGP2eVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTN5LkW5JI5O MlfTV2FPT0WU
CAL-39 M1HPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHqWGNKSzVyPUO3Mlkhdk1? MoXPV2FPT0WU
MN-60 M2DnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHqT3ZQUUN3ME2zO{46PiCwTR?= Ml\ZV2FPT0WU
RKO NG\NRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTN6LkOzJI5O M{PKZXNCVkeHUh?=
U251 Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL2dZFKSzVyPUO4MlQ{KG6P M3HwcnNCVkeHUh?=
SJSA-1 M2TVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTN6LkW0JI5O NXnvdpVQW0GQR1XS
CAL-12T M1flW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfXVIlKSzVyPUO4MlYhdk1? MoPGV2FPT0WU
HCC1419 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\JWmFYUUN3ME2zPE44OSCwTR?= NGfCfFVUSU6JRWK=
CO-314 NF7PbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTN6Lke0JI5O MoraV2FPT0WU
LB1047-RCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjBb4VKSzVyPUO4MlgyKG6P MlfBV2FPT0WU
A101D MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTN6Lkm3JI5O NXvrboNpW0GQR1XS
MDA-MB-175-VII MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS4dpZKSzVyPUO5MlUyKG6P NFLkT25USU6JRWK=
MZ2-MEL NH\qZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYq5V2oyUUN3ME2zPU43PiCwTR?= M3TXcnNCVkeHUh?=
NB5 NV;4bI9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXJboZyUUN3ME20NE43PCCwTR?= M1;4VnNCVkeHUh?=
G-401 Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGzW4k5UUN3ME20NE45OiCwTR?= NIXTV3BUSU6JRWK=
HT MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy0OXZmUUN3ME20NU4xOiCwTR?= M2LVUHNCVkeHUh?=
8305C MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTRzLki3JI5O MWfTRW5ITVJ?
BHY MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTR{LkeyJI5O NV6zTHB5W0GQR1XS
NTERA-S-cl-D1 NYLLS2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfsVo5uUUN3ME20N{BvVQ>? M1vvOHNCVkeHUh?=
T-24 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M365PWlEPTB;NEOuPFMhdk1? MnrUV2FPT0WU
EPLC-272H M331Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3u4SWlEPTB;NESuN|khdk1? MX;TRW5ITVJ?
PSN1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfoTWM2OD12ND60JI5O NE\YZVFUSU6JRWK=
NCI-H2452 NHvi[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTR2LkW4JI5O M4\oO3NCVkeHUh?=
KS-1 Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHEdVVKSzVyPUS0MlY3KG6P MV;TRW5ITVJ?
HD-MY-Z NIfJOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTR2LkmyJI5O MnvPV2FPT0WU
KNS-62 M4\uS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH1TWM2OD12NT6zPEBvVQ>? M4jhbnNCVkeHUh?=
NOMO-1 M171Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PBfmlEPTB;NEWuPFchdk1? Mn;mV2FPT0WU
SK-HEP-1 M1fQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D1V2lEPTB;NE[uNFQhdk1? MVPTRW5ITVJ?
IGR-1 MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPBTWM2OD12Nj6xN{BvVQ>? NWXCUodCW0GQR1XS
KYSE-180 NXvBdFlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\zTWM2OD12Nj6xO{BvVQ>? NGOxbHJUSU6JRWK=
EW-22 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TGbWlEPTB;NE[uNkBvVQ>? NHrkRmpUSU6JRWK=
NCI-H1355 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTafZBqUUN3ME20Ok4{PCCwTR?= MV7TRW5ITVJ?
DOHH-2 M2j2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL1VIExUUN3ME20Ok4{PyCwTR?= NETqXJdUSU6JRWK=
A4-Fuk M1y1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXwTWM2OD12Nj61NkBvVQ>? MWHTRW5ITVJ?
PC-14 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jZe2lEPTB;NE[uOVchdk1? M1PIfnNCVkeHUh?=
TE-5 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTvTWM2OD12Nj64OEBvVQ>? MX3TRW5ITVJ?
LB996-RCC M3XLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH22bpZKSzVyPUS3MlE6KG6P NF71VZBUSU6JRWK=
NCI-H1623 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTR5Lke2JI5O NYHic2N7W0GQR1XS
NCI-H1155 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfxdIJKSzVyPUS4MlMzKG6P M2TnWnNCVkeHUh?=
LoVo NVewUm9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfI[4ZKSzVyPUS4MlQhdk1? NIrIXmVUSU6JRWK=
MCF7 NGDJN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\LT5dKSzVyPUS4MlU5KG6P MXLTRW5ITVJ?
AGS MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPSTWM2OD12OD63O{BvVQ>? MmDHV2FPT0WU
PFSK-1 MkjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uxNGlEPTB;NEmuNFYhdk1? NXj4O25zW0GQR1XS
22RV1 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfEPXBKSzVyPUS5MlA6KG6P NEm2RW9USU6JRWK=
COR-L23 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnNTWM2OD12OT6xOkBvVQ>? MontV2FPT0WU
D-283MED MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXOTWM2OD12OT62NUBvVQ>? M2nCNnNCVkeHUh?=
SW982 M{TCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDUTWM2OD12OT65NUBvVQ>? MV3TRW5ITVJ?
SW620 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTCTnNpUUN3ME21NE4{PiCwTR?= MUPTRW5ITVJ?
KYSE-140 MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTGTWM2OD13MD61OUBvVQ>? M1vZSnNCVkeHUh?=
GCIY NVHzOZJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTVyLk[3JI5O NEfhfmdUSU6JRWK=
MHH-ESS-1 M2TWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnKfnlsUUN3ME21NU46PSCwTR?= M3j1Z3NCVkeHUh?=
D-423MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTkTWM2OD13Mj6wPEBvVQ>? MXHTRW5ITVJ?
SF539 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe5V49KSzVyPUWyMlM2KG6P NEfDOIlUSU6JRWK=
RPMI-2650 M4XDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvTeY9KSzVyPUWyMlY6KG6P NU\tPHVxW0GQR1XS
GR-ST MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnmOFZKSzVyPUWyMlg4KG6P MVHTRW5ITVJ?
YKG-1 M2nhe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTV|IH7N MoDQV2FPT0WU
SK-MES-1 M{DXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrtXXYxUUN3ME21N{4zPiCwTR?= MoTLV2FPT0WU
HLE NGraOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL6TWM2OD13Mz60O{BvVQ>? NXu5b5pCW0GQR1XS
RVH-421 NXTlPXh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPnWIxPUUN3ME21N{43PyCwTR?= MkTBV2FPT0WU
C32 NXzRVZFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTV|LkizJI5O Ml7wV2FPT0WU
GB-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;t[2lEPTB;NUSuNkBvVQ>? NEXhRlJUSU6JRWK=
SNB75 NILMbWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHlZotKSzVyPUW0MlI3KG6P NWLLTZdnW0GQR1XS
EM-2 M3HGUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\EeGlEPTB;NUSuOEBvVQ>? M3z0e3NCVkeHUh?=
RH-1 NGrQOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTV2Lkegcm0> MXHTRW5ITVJ?
NKM-1 Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXHS4duUUN3ME21OE45OSCwTR?= M4DIOHNCVkeHUh?=
NCI-H2405 NEXVSoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nifGlEPTB;NUSuPFghdk1? Mo\pV2FPT0WU
KYSE-450 M3LuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjRTWM2OD13NT6xOkBvVQ>? M{fBU3NCVkeHUh?=
A704 Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTV3LkW5JI5O MnSzV2FPT0WU
HAL-01 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTXZnpVUUN3ME21OU45OyCwTR?= M{\3VnNCVkeHUh?=
TE-11 M1rtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV[wNGJbUUN3ME21OU46QSCwTR?= M1\HVXNCVkeHUh?=
DOK NUnW[pRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDEXVZKSzVyPUW2MlAzKG6P MXPTRW5ITVJ?
KY821 NHn3VppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnDVJRKSzVyPUW2MlIhdk1? NULm[mZKW0GQR1XS
KGN M4DjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3v0Z2lEPTB;NU[uN|Ihdk1? MULTRW5ITVJ?
MC116 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\iU2lEPTB;NUeuPEBvVQ>? Mn\HV2FPT0WU
PANC-08-13 NXvBeYV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC2TWM2OD13OD6wNUBvVQ>? MUTTRW5ITVJ?
KE-37 NEjNfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTV6Lke3JI5O MmHPV2FPT0WU
KYSE-410 M3Tm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTV7LkS3JI5O MULTRW5ITVJ?
RO82-W-1 NXLCXmF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTV7Lkmgcm0> NWDWZ5lsW0GQR1XS
M14 NEDhcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHuUXJKSzVyPU[wMlA1KG6P NWPzdGlXW0GQR1XS
GI-1 MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTZyLkOgcm0> NHm5No1USU6JRWK=
ML-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnMTWM2OD14MD62NkBvVQ>? NFm2eJpUSU6JRWK=
BFTC-905 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[2WmlEPTB;NkCuOlUhdk1? NIflVppUSU6JRWK=
DMS-273 M3jBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTZyLki3JI5O NFjUVItUSU6JRWK=
MDA-MB-361 NFXCUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Hpb2lEPTB;NkGgcm0> MkPSV2FPT0WU
MSTO-211H M4rDRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTZ|LkWxJI5O NGLIblBUSU6JRWK=
MEG-01 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PINWlEPTB;NkOuOVIhdk1? M{\FZ3NCVkeHUh?=
M059J M4rqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTZ|LkW4JI5O NYDCPZRDW0GQR1XS
LN-405 M{fCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TtPGlEPTB;NkOuPFUhdk1? MVnTRW5ITVJ?
NCI-H1581 MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\qO2ZKSzVyPU[0MlA{KG6P MYrTRW5ITVJ?
TCCSUP MlXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XjXWlEPTB;NkSuOVMhdk1? NVXRfXVvW0GQR1XS
SW872 M1H3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LFNWlEPTB;NkSuOVchdk1? Mn3vV2FPT0WU
KYSE-510 M{fTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL5XFJYUUN3ME22OU44PSCwTR?= NI[3O4hUSU6JRWK=
NCI-H1792 M1jFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W5S2lEPTB;Nk[uNVUhdk1? M2LMNnNCVkeHUh?=
SW13 NFr2e4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn64TWM2OD14Nj61JI5O NITodVJUSU6JRWK=
TE-8 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTZ4LkWyJI5O NYntb5V[W0GQR1XS
SCH MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTZ5LkGgcm0> M4XVeXNCVkeHUh?=
NEC8 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;sS4NiUUN3ME22O{4zPCCwTR?= NVTLNFAzW0GQR1XS
HuO-3N1 NEjqZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELTN4pKSzVyPU[3MlMyKG6P MoLzV2FPT0WU
EFM-19 NHXGRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTZ5LkWgcm0> NWWw[lBxW0GQR1XS
HEC-1 M1PtXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDpTWM2OD14Nz61NkBvVQ>? MVLTRW5ITVJ?
T47D MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPJWJFiUUN3ME22O{45PyCwTR?= MkPHV2FPT0WU
SNU-423 M37XTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHnN4ZoUUN3ME22O{46QCCwTR?= MYrTRW5ITVJ?
WM-115 MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrkTWM2OD14OD6xOEBvVQ>? MlrkV2FPT0WU
CaR-1 M{jvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTZ6LkK1JI5O MkPsV2FPT0WU
KU812 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHtV|RKSzVyPU[4MlY6KG6P NF3ROpVUSU6JRWK=
AM-38 NVHMbIlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT0T3dkUUN3ME22PU4{OSCwTR?= MmH0V2FPT0WU
KOSC-2 MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ryNGlEPTB;NkmuPVchdk1? MoDTV2FPT0WU
MC-IXC Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljxTWM2OD15MD6wPEBvVQ>? MkPlV2FPT0WU
SCC-4 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTdzLkO4JI5O NIPQc3dUSU6JRWK=
Calu-3 NXTqNIZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\tZnBKSzVyPUexMlk5KG6P MUPTRW5ITVJ?
RPMI-8866 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\z[mlxUUN3ME23Nk45OiCwTR?= M1jlTXNCVkeHUh?=
OVCAR-4 MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTd|LkO2JI5O NE\4[WRUSU6JRWK=
OAW-42 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PRdGlEPTB;N{OuN|khdk1? Mnr1V2FPT0WU
ATN-1 M2PGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLBXHFKSzVyPUezMlg4KG6P MYXTRW5ITVJ?
CHP-212 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\tfmlEPTB;N{SuPVUhdk1? MX7TRW5ITVJ?
C2BBe1 NWnVN4tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33nR2lEPTB;N{WuNFMhdk1? NHf2OHlUSU6JRWK=
A498 MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjScnVKSzVyPUe1MlE2KG6P MVLTRW5ITVJ?
SH-4 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTd3LkKxJI5O NHXPWmRUSU6JRWK=
SNU-449 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYiwdWpCUUN3ME23OU44QSCwTR?= NILremtUSU6JRWK=
RD NWTSeo5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;Sd2lEPTB;N{WuPFYhdk1? M4TqUnNCVkeHUh?=
PANC-03-27 Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfDTWM2OD15Nj6yOUBvVQ>? NVLFUpNTW0GQR1XS
S-117 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLSTWM2OD15Nj6yO{BvVQ>? MlTGV2FPT0WU
SK-MEL-2 NW\aNFl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHrTWM2OD15Nj63OUBvVQ>? M3ywUnNCVkeHUh?=
LK-2 M2ntT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTd5LkC1JI5O MVjTRW5ITVJ?
CP50-MEL-B M3LyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHP[45VUUN3ME23O{41KG6P M3HtNHNCVkeHUh?=
647-V NV;PS2NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe0TWM2OD15OD6wO{BvVQ>? NHvLVYlUSU6JRWK=
LU-134-A NHn5OndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfyfWNlUUN3ME23PU4xOyCwTR?= NE\2eHNUSU6JRWK=
5637 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3DdVJKSzVyPUe5MlI{KG6P NXjh[FIyW0GQR1XS
NCI-H1437 NEO4PXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljNTWM2OD16MD61JI5O NWjQVGtrW0GQR1XS
NCI-H460 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTIPYw2UUN3ME24NU4zOyCwTR?= MWLTRW5ITVJ?
BxPC-3 NV\0bpNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\JVXJKSzVyPUixMlQ3KG6P NVvtc3ZsW0GQR1XS
CAN MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrPTWM2OD16MT64OEBvVQ>? NFjQOYpUSU6JRWK=
KINGS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D1c2lEPTB;OEKuN|Ihdk1? MkLQV2FPT0WU
OCUB-M MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTh{LkSxJI5O M4jFZnNCVkeHUh?=
KALS-1 NGfpSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2wTWM2OD16Mj61OEBvVQ>? MkLwV2FPT0WU
OCI-AML2 NYq3NYlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnoTWM2OD16Mj62NUBvVQ>? M2jidHNCVkeHUh?=
A253 NEHqWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS5UGg6UUN3ME24Nk43PSCwTR?= Mki4V2FPT0WU
LCLC-97TM1 NIDYXXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTh{Lki2JI5O MXrTRW5ITVJ?
NCI-H520 NFjwVJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2ntfmlEPTB;OEOuNFYhdk1? MWHTRW5ITVJ?
P30-OHK MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1znc2lEPTB;OEOuOUBvVQ>? NXf5So5JW0GQR1XS
SBC-5 M4TzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTh|LkWyJI5O Ml7uV2FPT0WU
HCE-T NWnXOm5CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7uOWZKSzVyPUizMlc1KG6P MYnTRW5ITVJ?
JEG-3 NXfjW21iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X1fmlEPTB;OESuNUBvVQ>? Mny0V2FPT0WU
KG-1 MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzBeZBPUUN3ME24OE4zPCCwTR?= MlfkV2FPT0WU
MIA-PaCa-2 MoW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTh2LkW0JI5O M1jlbnNCVkeHUh?=
CAL-33 NWi1RY9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnqPVNXUUN3ME24OU4xQCCwTR?= NInoXnhUSU6JRWK=
639-V MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vwNWlEPTB;OEWuOFIhdk1? NWDDS5VxW0GQR1XS
NCI-H1048 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHITWtyUUN3ME24Ok4{OSCwTR?= NHG3OYpUSU6JRWK=
NCI-H1573 NVH4dXNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\jTodKSzVyPUi3MlQ5KG6P MkDtV2FPT0WU
NCI-H2228 M4L4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPqe5J{UUN3ME24PE4zPiCwTR?= NI\iVHpUSU6JRWK=
NB14 M3XvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXicIdKSzVyPUi4MlMhdk1? NV3qXZJwW0GQR1XS
SCC-25 NGXW[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3SwXGlEPTB;OEmuPFIhdk1? M33IenNCVkeHUh?=
A431 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmToTWM2OD16OT65O{BvVQ>? NVTmc2tzW0GQR1XS
SN12C MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn3dFlKSzVyPUmwMlYzKG6P MljFV2FPT0WU
HuCCT1 NEXkdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r5R2lEPTB;OUCuO|Yhdk1? MnLLV2FPT0WU
LS-123 MkjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfkUo5KSzVyPUmyMlE5KG6P MWDTRW5ITVJ?
CAL-85-1 NHz4cplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe3foRlUUN3ME25Nk41QCCwTR?= NF7TPGVUSU6JRWK=
ES6 NVrmTI1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L6UGlEPTB;OUKuPFMhdk1? NYXocJltW0GQR1XS
NCI-H650 M4\o[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH6SFVuUUN3ME25OE4xQSCwTR?= MkTwV2FPT0WU
NCI-H446 NVHJRnRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXz1V4REUUN3ME25OU4yOiCwTR?= M3XpZ3NCVkeHUh?=
EW-13 MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWntdmloUUN3ME25OU44PSCwTR?= NH\3PIRUSU6JRWK=
HSC-2 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljZTWM2OD17NT64PUBvVQ>? NIG2UVNUSU6JRWK=
U031 NVn5[2pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIf1S|hKSzVyPUm2Mlc{KG6P MX\TRW5ITVJ?
EW-11 NFWz[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH6TWM2OD17Nj64PEBvVQ>? Mn3rV2FPT0WU
GAK MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTl6LkmzJI5O M2C3fHNCVkeHUh?=
SK-OV-3 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHlTWM2OD1zMECuNFchdk1? NFO5d|lUSU6JRWK=
OMC-1 M4PJUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFztNIdKSzVyPUGwNE4yQCCwTR?= MWjTRW5ITVJ?
TK10 MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:zVmlEPTB;MUCwMlIyKG6P M{fiU3NCVkeHUh?=
EKVX NHTPWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[wOFZKSzVyPUGwNE43KG6P MmXPV2FPT0WU
Detroit562 NIDWdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu2RnBKSzVyPUGwNk4yPyCwTR?= Mm\RV2FPT0WU
SF268 M333NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i0e2lEPTB;MUCyMlM1KG6P NX;MdXZmW0GQR1XS
SNU-387 Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL3XWc3UUN3ME2xNFQvOTdibl2= NEflV5VUSU6JRWK=
MDA-MB-231 NH;CUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTFyNT6wOkBvVQ>? MVLTRW5ITVJ?
NCI-H1563 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfDTWM2OD1zMEWuNVghdk1? NV7rWYhyW0GQR1XS
D-502MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKzcFJKSzVyPUGwOU44KG6P NWnvOoU6W0GQR1XS
A2780 M3LGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFezZ3hKSzVyPUGwOk41PyCwTR?= MnnVV2FPT0WU
IA-LM MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFyNz61NUBvVQ>? NFu0U5hUSU6JRWK=
D-392MG MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7WbGdKSzVyPUGwO{42PCCwTR?= MkHsV2FPT0WU
MS-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDoVWxKSzVyPUGwO{44OSCwTR?= NHPnWJRUSU6JRWK=
SW1990 NFq1UnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX2y[mJUUUN3ME2xNFgvPTRibl2= MVnTRW5ITVJ?
HEL M33XWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3FeZdKUUN3ME2xNFkvOjlibl2= MX\TRW5ITVJ?
SW1573 NHvHXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvpTWM2OD1zMEmuN|Ehdk1? NVfvcHFDW0GQR1XS
SW1783 NYL6NnZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFzMD6yNkBvVQ>? NV:4TWI5W0GQR1XS
COLO-680N MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPMTWM2OD1zMUCuO|Yhdk1? M1vQN3NCVkeHUh?=
NCI-N87 NXjGXpU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPITWM2OD1zMUGuNFQhdk1? NIrhSYlUSU6JRWK=
SK-MEL-28 NYrXV|ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf0TWM2OD1zMUGuOVUhdk1? MmXKV2FPT0WU
BT-20 NEfoW|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\TS5hpUUN3ME2xNVIvODFibl2= NVPqdVFIW0GQR1XS
NCI-H1648 NGTDUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF[2TppKSzVyPUGxN{BvVQ>? NXnUS29iW0GQR1XS
no-11 NGGx[YRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIniUIdKSzVyPUGxN{4zQCCwTR?= NXiyOHZjW0GQR1XS
MOLT-13 NYDT[5dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zMTWlEPTB;MUGzMlQ1KG6P M1HVRnNCVkeHUh?=
NCI-H2170 M{W0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELY[G1KSzVyPUGxOE42OSCwTR?= M1HzNXNCVkeHUh?=
HTC-C3 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFzNj64OUBvVQ>? NWjVNJlZW0GQR1XS
LU-99A NIraNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HNdmlEPTB;MUG3MlIyKG6P MmizV2FPT0WU
HCC2998 M3rrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYqxU21xUUN3ME2xNVcvQTJibl2= MmrUV2FPT0WU
NB13 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\4[pIyUUN3ME2xNVcvQTlibl2= NH76ZmpUSU6JRWK=
GT3TKB MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnxTWM2OD1zMUiuNFghdk1? MnjnV2FPT0WU
BT-549 NF;QV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7FO45KSzVyPUGxPE46PSCwTR?= Mm\mV2FPT0WU
NCI-H747 Mn;kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXSXmZKSzVyPUGxPU4{PCCwTR?= M33peHNCVkeHUh?=
EW-1 NULrSHVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF{MD6yJI5O MXHTRW5ITVJ?
LB831-BLC NUDLUot5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf0TWM2OD1zMkCuOlMhdk1? NGmzO4FUSU6JRWK=
NMC-G1 M4PYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPDXpB6UUN3ME2xNlEvOTFibl2= NYruUJZvW0GQR1XS
COLO-679 NFLmXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUC3U4RjUUN3ME2xNlIvOTVibl2= M1PlS3NCVkeHUh?=
HL-60 M2HBbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLjTWM2OD1zMkOuNUBvVQ>? M{jLWXNCVkeHUh?=
MKN7 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojtTWM2OD1zMkOuPFMhdk1? NFPkbYpUSU6JRWK=
RERF-LC-MS MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfBTWM2OD1zMkSuN|Ehdk1? MXjTRW5ITVJ?
DMS-114 NXzte2lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjCV5VoUUN3ME2xNlUvODlibl2= NIO1bpdUSU6JRWK=
HuP-T4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm2TWM2OD1zMk[uPVchdk1? M1H5WHNCVkeHUh?=
HCC2157 MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGwTWM2OD1zMkeuOUBvVQ>? M3;TRXNCVkeHUh?=
SKG-IIIa NWm2WWpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrJOIZFUUN3ME2xNlgvQCCwTR?= NH:xRYhUSU6JRWK=
HCT-116 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTHbG5SUUN3ME2xN|AvPjRibl2= M4K2T3NCVkeHUh?=
BB30-HNC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrFTHN{UUN3ME2xN|AvPzhibl2= NWn4U5dEW0GQR1XS
KYSE-270 NUnGUVI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7DW2NKSzVyPUGzNE45QCCwTR?= MoPXV2FPT0WU
MFM-223 M3HiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvYTWM2OD1zM{GuOVEhdk1? NVS3T5RPW0GQR1XS
NH-12 NWLYOZk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjhTWM2OD1zM{KuPVkhdk1? M3GxcnNCVkeHUh?=
U-118-MG NXT3R|FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\JPGlEPTB;MUOzMlYzKG6P NIfnXFhUSU6JRWK=
ESS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3HcFd7UUN3ME2xN|UvOThibl2= Ml3LV2FPT0WU
D-247MG M4HXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfScldKUUN3ME2xN|UvOjFibl2= NUfTdJF[W0GQR1XS
IGROV-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TtSGlEPTB;MUO1Mlc3KG6P Ml\EV2FPT0WU
C-33-A NED3b5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XoWGlEPTB;MUO1Mlk4KG6P NWLhfIQ{W0GQR1XS
NCI-H1693 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonDTWM2OD1zM{[uNVIhdk1? MXjTRW5ITVJ?
MLMA NV\oS2RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\XTWM2OD1zM{[uOVghdk1? NEnxc4RUSU6JRWK=
SK-N-AS NVPs[IhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\FWmpJUUN3ME2xN|cvOTdibl2= NI\xdo5USU6JRWK=
NCI-H1755 NEftXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7sTWM2OD1zM{iuPFUhdk1? MWDTRW5ITVJ?
CHP-134 NIfpVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrvTWM2OD1zM{muOVUhdk1? MlnmV2FPT0WU
LS-513 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2O2XWlEPTB;MUSwMlkyKHCP M{\1fXNCVkeHUh?=
TE-12 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[4RWlEPTB;MUSwMlk{KG6P NGn5bllUSU6JRWK=
KNS-42 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XHO2lEPTB;MUS0MlMhdk1? MmT3V2FPT0WU
SJRH30 NE\mR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjiVWdKSzVyPUG0OE41PCCwTR?= MnHQV2FPT0WU
NCI-H1092 NVP0VI9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTF2ND61NkBvVQ>? M37HOHNCVkeHUh?=
H-EMC-SS NGruSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF2Nj64NUBvVQ>? NXXse|VlW0GQR1XS
SK-MEL-3 NXvzZpV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF2Nz61OUBvVQ>? M{n1T3NCVkeHUh?=
SK-N-FI MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITvXW9KSzVyPUG0O{42QSCwTR?= NHHMSVNUSU6JRWK=
NCI-H2126 MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S1Z2lEPTB;MUS4MlE2KG6P NHnlNllUSU6JRWK=
NCI-H1299 NXPIdWt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrBfW1KSzVyPUG1NE4zOiCwTR?= M3;aR3NCVkeHUh?=
CFPAC-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETWTmJKSzVyPUG1NE43PiCwTR?= M2f4fHNCVkeHUh?=
NCI-H661 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF3MT6yOkBvVQ>? MlnYV2FPT0WU
KYSE-70 NX72UGhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjwcYd4UUN3ME2xOVEvPzlibl2= MVLTRW5ITVJ?
SW900 Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\lTWM2OD1zNUSuOlUhdk1? Mki2V2FPT0WU
Ca-Ski M1TReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonoTWM2OD1zNU[uN|khdk1? Mor3V2FPT0WU
HPAF-II M{i2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXpemJrUUN3ME2xOVYvPDdibl2= NY[1PXNYW0GQR1XS
LB2518-MEL NW\RN45uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoexTWM2OD1zNUeuNUBvVQ>? MVXTRW5ITVJ?
LC-2-ad M1HqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfCUnVKSzVyPUG1PE43OiCwTR?= M2fNOnNCVkeHUh?=
HCC1806 M2jFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P4SGlEPTB;MU[3Mlg5KG6P NV;nXpFtW0GQR1XS
UACC-62 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\MTWM2OD1zNkiuNFkhdk1? MmrUV2FPT0WU
KM-H2 NUnXOYdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O3eGlEPTB;MUewMlU5KG6P MUHTRW5ITVJ?
NCI-H2347 M3:w[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;GRlFKSzVyPUG3Nk44OiCwTR?= Mnf4V2FPT0WU
SCC-15 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\HemlEPTB;MUezMlY3KG6P NVPIWVVLW0GQR1XS
BB49-HNC M{DycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXroRmJoUUN3ME2xO|MvQDFibl2= M1fBSnNCVkeHUh?=
GMS-10 NELq[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jCXGlEPTB;MUezMlk1KG6P MXTTRW5ITVJ?
NCI-H2052 NYLzN3Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTF5ND65JI5O NXPSSFFVW0GQR1XS
SW626 NWDqRnNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF5Nj6wOkBvVQ>? Mn3OV2FPT0WU
MDA-MB-415 NV7oTpo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7yZoZ1UUN3ME2xO|YvPjFibl2= Ml7TV2FPT0WU
Saos-2 NXnYXJVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnOZVduUUN3ME2xO|kvOzVibl2= NXrWe45[W0GQR1XS
DK-MG NUnxPWRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF6MD6zJI5O MlTQV2FPT0WU
SNU-C2B MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HPTmlEPTB;MUiwMlc{KG6P NXXhenBXW0GQR1XS
A427 M2LzS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTF6Mj61O{BvVQ>? M13aTXNCVkeHUh?=
KP-N-YS MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf0WJdKSzVyPUG4OUBvVQ>? MnrmV2FPT0WU
J82 MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3UTZk1UUN3ME2xPFUvOThibl2= MUXTRW5ITVJ?
LS-411N NYXl[nNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DjVWlEPTB;MUi3MlI5KG6P MVzTRW5ITVJ?
HCC1937 NWLrdmNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTF6Nz60PUBvVQ>? NH7Ye|ZUSU6JRWK=
OE33 M3rmd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\LTWM2OD1zOEiuPVchdk1? NGLENZNUSU6JRWK=
NB7 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPSfo1KSzVyPUG4PU45QSCwTR?= MkfIV2FPT0WU
SW684 M3P2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvkZXdLUUN3ME2xPVYvOTNibl2= NYr4fHhtW0GQR1XS
HT-144 Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXRTWM2OD1zOU[uNVUhdk1? MWjTRW5ITVJ?
SK-MEL-30 NU\KZVBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHyTWM2OD1zOU[uNkBvVQ>? MXvTRW5ITVJ?
DBTRG-05MG NX3GV49mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF7OD60O{BvVQ>? NIT6TpZUSU6JRWK=
NCI-H1395 NHvRS5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP4c5ZZUUN3ME2xPVgvQDVibl2= NV60elM3W0GQR1XS
NCI-H2122 M2H0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYWzZ4FbUUN3ME2yNFAvPTlibl2= Mli2V2FPT0WU
no-10 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfVfJJKSzVyPUKwNU4xPCCwTR?= MYjTRW5ITVJ?
SW48 NWHYTHozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7NOY1KSzVyPUKwNU4{OSCwTR?= M1fzSHNCVkeHUh?=
NCI-H1650 NFTXXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nhOGlEPTB;MkC0MlAyKG6P NVjQT5k6W0GQR1XS
MZ1-PC NGPudVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJyNT61PEBvVQ>? MkT6V2FPT0WU
U-266 NYK3bpFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrXfJJKSzVyPUKwOU44QSCwTR?= NVjySppbW0GQR1XS
CAS-1 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVy4[FR4UUN3ME2yNFcvPDRibl2= NGn1NppUSU6JRWK=
AU565 NUHscnhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJzMj64NkBvVQ>? NXnlXZJwW0GQR1XS
UACC-257 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq5O3lKSzVyPUKxN{46QSCwTR?= M3e5e3NCVkeHUh?=
CAL-27 NXTTTZVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXO[YVKSzVyPUKxO{4xPSCwTR?= M1m2PXNCVkeHUh?=
NCI-H23 M1zV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHxXWw6UUN3ME2yNVkvOzNibl2= MkXYV2FPT0WU
TE-6 NGX3TJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHyUFRWUUN3ME2yNVkvPjhibl2= M2njWXNCVkeHUh?=
TGBC24TKB NE\4eGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPFU3ZKSzVyPUKyNk4yPyCwTR?= NFvWUG1USU6JRWK=
TE-1 NHG4TGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfqTWM2OD1{MkKuPFghdk1? M1HMRnNCVkeHUh?=
RCC10RGB MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJ{ND6xPUBvVQ>? NGHEbIhUSU6JRWK=
NCI-H596 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnHbnN5UUN3ME2yNlgvOjJibl2= MlPRV2FPT0WU
SW954 M1X6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rud2lEPTB;MkOzMlg{KG6P MmjtV2FPT0WU
NCI-H2087 NV;XRYh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[4SW8xUUN3ME2yN|QvPTFibl2= MWjTRW5ITVJ?
SK-PN-DW NVLpdVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJ|NT6xPUBvVQ>? M1i1VHNCVkeHUh?=
KM12 NFLqephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\hZ3RDUUN3ME2yN|UvPyCwTR?= MkHXV2FPT0WU
BT-474 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnx[o9KSzVyPUKzOU44OyCwTR?= NHH4OmVUSU6JRWK=
IST-MES1 NEfBPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jxOmlEPTB;MkO2MlU4KG6P NH;OSoJUSU6JRWK=
HT-1197 M4TQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHKTWM2OD1{M{iuNFkhdk1? M1LLZXNCVkeHUh?=
CAL-54 Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;tbWFKSzVyPUKzPE41QSCwTR?= NYLYWVhbW0GQR1XS
NB10 M3rDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XtSGlEPTB;MkSwMlA3KG6P NHPiSVVUSU6JRWK=
PANC-10-05 NVH3N21lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjYOYUyUUN3ME2yOFUvPTZibl2= NV31W3FwW0GQR1XS
NCI-H522 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXNR3RKSzVyPUK0PE4{OSCwTR?= MlzSV2FPT0WU
A388 NFW4RYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:4fnhKSzVyPUK0PU45OiCwTR?= M2DhTXNCVkeHUh?=
GOTO M1LUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ3MD6yPUBvVQ>? NGS1ZWtUSU6JRWK=
KLE Mn:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ3MT64O{BvVQ>? NWP1RmxtW0GQR1XS
KYSE-520 NGDyO4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XZcWlEPTB;MkWyMlg3KG6P MoDsV2FPT0WU
HCE-4 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:4XYxKSzVyPUK2Nk42KG6P M3roc3NCVkeHUh?=
KURAMOCHI M3\yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvrTWM2OD1{NkWuPUBvVQ>? MnzmV2FPT0WU
HCC38 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf3fohKSzVyPUK2Ok41QCCwTR?= MV;TRW5ITVJ?
FADU MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ4Nj62N{BvVQ>? MYHTRW5ITVJ?
CW-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\acWlEPTB;Mk[5Mlk3KG6P MWLTRW5ITVJ?
L-428 NFXjOmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ5NT6xOUBvVQ>? NVLOUXVEW0GQR1XS
HCC1569 MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PWOmlEPTB;Mke1Mlg1KG6P M3HLXHNCVkeHUh?=
NCI-H810 NWXvU2pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfCSVJKSzVyPUK3PE4{OSCwTR?= NG\QXWZUSU6JRWK=
LB771-HNC NVrTW4xbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLhTWM2OD1{OEWuPFQhdk1? MkW3V2FPT0WU
LCLC-103H MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\SO2lEPTB;Mki1Mlk6KG6P MkC4V2FPT0WU
EFO-21 M3TESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml25TWM2OD1{OEeuOlghdk1? M3jSOnNCVkeHUh?=
CAL-72 M4W0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ7Mz6xPUBvVQ>? Mki4V2FPT0WU
SCC-9 NWjWNXJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK3c5V{UUN3ME2yPVMvOjJibl2= MlHxV2FPT0WU
COLO-829 NFT5d4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH1OYFKSzVyPUK5Ok42KG6P MXnTRW5ITVJ?
U-87-MG MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LkUmlEPTB;M{CwMlc{KG6P NH\NVWNUSU6JRWK=
MZ7-mel MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnkWVhsUUN3ME2zNlMvPzZibl2= NHLyXYZUSU6JRWK=
NCI-H1770 NGniZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\NVmlEPTB;M{K2Mlc1KG6P M3:0WnNCVkeHUh?=
ChaGo-K-1 NYPPR3RmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonETWM2OD1|MkiuNUBvVQ>? NUTiTnNoW0GQR1XS
SiHa MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfBSHRKSzVyPUOyPU4zPCCwTR?= M3;HS3NCVkeHUh?=
NCI-SNU-5 NWC2d21HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\oTWM2OD1|M{[uO|chdk1? M1jKSHNCVkeHUh?=
DJM-1 NXuyVmdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnH[XE2UUN3ME2zOFAvOzNibl2= MV;TRW5ITVJ?
OE19 M2Dnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnKTWlKSzVyPUO0NE42OyCwTR?= MljSV2FPT0WU
NCI-H1651 M3;zdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfJcoJKSzVyPUO0OE4yQCCwTR?= MVPTRW5ITVJ?
COLO-792 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTN3ND60NkBvVQ>? MVfTRW5ITVJ?
ACHN NX\nWlBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvMbllKSzVyPUO1Ok44OSCwTR?= MYrTRW5ITVJ?
TH-3 NHTrZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTN5OT65OUBvVQ>? NFzjXllUSU6JRWK=
HT-1376 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTN6ND64PEBvVQ>? M2TZeHNCVkeHUh?=
RH-18 NH;FNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL6RZFKSzVyPUO5OE44PCCwTR?= M{jsS3NCVkeHUh?=
NB6 NWrQfHNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTN7Nj62OkBvVQ>? MofyV2FPT0WU
COLO-320-HSR NVG4OoJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPOTWM2OD12MEOuN|chdk1? M3jVW3NCVkeHUh?=
UACC-893 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTRyNj60O{BvVQ>? NEfETGNUSU6JRWK=
DSH1 M2HWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWqzbYVsUUN3ME20NFYvQTFibl2= MX7TRW5ITVJ?
TE-10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDYTWM2OD12MEeuNFEhdk1? NEfCdXBUSU6JRWK=
HCC70 Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fuS2lEPTB;NEC5MlIyKG6P NVLHblJyW0GQR1XS
TGBC11TKB NGLLPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHYUW9KSzVyPUSxNE4{OyCwTR?= Mn7tV2FPT0WU
NCI-H727 NEXId|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTRzMj6xNUBvVQ>? NYOzeohjW0GQR1XS
ALL-PO Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTRzNT62PUBvVQ>? MoPVV2FPT0WU
ABC-1 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TCW2lEPTB;NEKwMlQ2KG6P MYTTRW5ITVJ?
NCI-H69 NGnNeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPEcph5UUN3ME20NlYvPzZibl2= MnnDV2FPT0WU
GP5d MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLxTWM2OD12M{SuOFEhdk1? MVzTRW5ITVJ?
UMC-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXn1dWk1UUN3ME20OVgvOzZibl2= NHv0No9USU6JRWK=
RMG-I M3flTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{faXmlEPTB;NE[3MlU3KG6P MoPTV2FPT0WU
YAPC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTR7MD62JI5O NG\3dnJUSU6JRWK=
LS-1034 NHq4[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPzU4g{UUN3ME20PVEvODZibl2= M3LrTHNCVkeHUh?=
RCM-1 M{e1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTPTWM2OD12OU[uOlghdk1? NGSycmxUSU6JRWK=
HCC1954 NFjxUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnVb4JKSzVyPUWxNk42KG6P MWPTRW5ITVJ?
SK-MEL-24 M3rO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD4TWlKSzVyPUWxOk42OSCwTR?= MW\TRW5ITVJ?
NB12 M2rTW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXHTWM2OD13MkiuOFIhdk1? M2LyZXNCVkeHUh?=
SW756 M1rGeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3qTWM2OD13NUSuPVYhdk1? NEXXUJJUSU6JRWK=
HCC1187 NF\aXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTV5NT64N{BvVQ>? NVPU[GpEW0GQR1XS
NCI-H2342 NY\xdVM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3pOmFKSzVyPUW5NE4{QSCwTR?= MX;TRW5ITVJ?
NCI-H2291 NIHr[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnOe2xKSzVyPUW5PE4{OSCwTR?= MYXTRW5ITVJ?
OVCAR-3 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluwTWM2OD13OUiuPVYhdk1? MV;TRW5ITVJ?
MHH-NB-11 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfzTWM2OD14MkmuNFEhdk1? MkTlV2FPT0WU
SAS NF2xWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfqZYdmUUN3ME22OVIvPjdibl2= NULCV3hFW0GQR1XS
COLO-824 M2DDO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HpdmlEPTB;Nki5MlM4KG6P MlLqV2FPT0WU
HCC1395 NYXlVXhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTZ7OD61JI5O NHPtUHFUSU6JRWK=
COLO-668 NEfuSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTdyNj6xJI5O MYrTRW5ITVJ?
NCI-H226 M3nSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XMW2lEPTB;N{C3Mlghdk1? MmHpV2FPT0WU
NB17 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz6Z3dKSzVyPUeyNU44PSCwTR?= MWXTRW5ITVJ?
SW1463 NEm4PHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnvWYlDUUN3ME23N|kvOTlibl2= MnzuV2FPT0WU
TGW M{L2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7v[npKSzVyPUe2NE4yPSCwTR?= NEjBXG1USU6JRWK=
NCI-H526 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rVbmlEPTB;OEKzMlU{KG6P MV7TRW5ITVJ?
COR-L88 NXrSepRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTh2OD6xNkBvVQ>? M4fXNnNCVkeHUh?=
NCI-H441 M1nqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\3OmlEPTB;OEm1MlIzKG6P NWrXWFN{W0GQR1XS
NCI-H630 NHi5XJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzHTWM2OD17MUKuPVYhdk1? NYLoWopkW0GQR1XS
Mo-T Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTl2Nz64PEBvVQ>? M1PDOnNCVkeHUh?=
JAR NVrlV|FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq4ZldtUUN3ME25OVYvOjRibl2= NHLKVnRUSU6JRWK=
NCI-H1838 MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW0TpNKSzVyPUGuNFI{QDhizszN MkTtV2FPT0WU
DoTc2-4510 NEm4elZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M365[GlEPTB;MT6wO|M4PiEQvF2= NIHNV|hUSU6JRWK=
MKN28 M1z5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKyeIVKSzVyPUGuNFkxOjRizszN NHfNOYhUSU6JRWK=
HuP-T3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG4TWM2OD1zLkGxPVA2KM7:TR?= NX\LN5NGW0GQR1XS
TE-9 MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3JOFNpUUN3ME2xMlEzQTd|IN88US=> NE\RWHFUSU6JRWK=
NY MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWWxUmY1UUN3ME2xMlE3Pzl{IN88US=> NEPIUWtUSU6JRWK=
HT55 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\USoM{UUN3ME2xMlMyOzR2IN88US=> MmT6V2FPT0WU
SW837 NVPzcZFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwM{K5O|gh|ryP NWDWUnVIW0GQR1XS
NCI-H2029 M4TW[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTFwNEG3PVEh|ryP NXjRfHBlW0GQR1XS
IST-SL1 Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXPTWM2OD1zLkS0NlQh|ryP MWDTRW5ITVJ?
COLO-741 M{n1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwNEm3O|Eh|ryP Ml7NV2FPT0WU
LU-65 NGexVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXjNFlKSzVyPUGuOlIzPDlizszN MXzTRW5ITVJ?
NCI-H1304 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f1S2lEPTB;MT62OVQ6QCEQvF2= MkP3V2FPT0WU
KARPAS-299 Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnWzTWM2OD1zLke5OFc6KM7:TR?= M3X1bXNCVkeHUh?=
NCI-H358 NXi4b48zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2yTWM2OD1zLkm1OVA{KM7:TR?= M{fvT3NCVkeHUh?=
OAW-28 M1jUTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjjTWM2OD1{LkC2PVE6KM7:TR?= M4PiNXNCVkeHUh?=
C8166 M{PLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJwNkOzPVIh|ryP MXLTRW5ITVJ?
COLO-678 NF3nXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHxTWM2OD1{LkizO|Y5KM7:TR?= NW\4PWppW0GQR1XS
SK-N-DZ M3POUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrQbGRKSzVyPUKuPFY{QDFizszN Ml6wV2FPT0WU
NCI-H82 MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJwOUCzOlkh|ryP MWDTRW5ITVJ?
JVM-2 NFjwSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNwMEOxPFgh|ryP MWnTRW5ITVJ?
SW1116 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTxTWM2OD1|LkC1OFEyKM7:TR?= NWrq[oVDW0GQR1XS
MDA-MB-453 M4LGbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTNwMUC0N|kh|ryP NVnvSpZ7W0GQR1XS
Calu-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfMTWM2OD1|LkG5PVch|ryP M3LpeXNCVkeHUh?=
SHP-77 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTNwNUK4JO69VQ>? MVTTRW5ITVJ?
Capan-2 MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTRwM{K1PFEh|ryP NHW3d2RUSU6JRWK=
SW948 MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTRwN{S3O|kh|ryP MlrtV2FPT0WU
HDLM-2 NIe5cWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jD[2lEPTB;NT6wO|czPSEQvF2= M1rzbXNCVkeHUh?=
LAN-6 M{X1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInPN|dKSzVyPU[uNlE1QTVizszN MUHTRW5ITVJ?
LU-135 NYTWXpBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTZwNEOwO|ch|ryP NEPSZXdUSU6JRWK=
T84 NFHzfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXwWGE2UUN3ME22Mlk5PjRizszN MWLTRW5ITVJ?
CAPAN-1 MmnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX1ZZdKSzVyPUeuOlIzOzNizszN NIPJNYpUSU6JRWK=
SW1417 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTLTWM2OD15LkmxO|MyKM7:TR?= MVXTRW5ITVJ?
BALL-1 NHrGT4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXSToRKSzVyPUiuOVA1ODlizszN MVjTRW5ITVJ?
HT-29 MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXJTWM2OD17LkC3OVk6KM7:TR?= MXTTRW5ITVJ?
C3A NFHEU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTWTWM2OD17Lki4N|k1KM7:TR?= MXrTRW5ITVJ?
NCI-H1993 NUnSN|lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXmcodKSzVyPUGwMlUxQDFizszN NX6zO4JjW0GQR1XS
SK-MEL-1 NIf2e|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jxc2lEPTB;MUGuOlI5QSEQvF2= MlT6V2FPT0WU
DU-145 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF2LkWwOVIh|ryP NIGydnpUSU6JRWK=
KP-N-YN NWL3fnZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX6fFdKSzVyPUG0MlUyODNizszN NEmyVpZUSU6JRWK=
CCRF-CEM NXvBT49{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTF2Lke4NFkh|ryP NVLJfIpWW0GQR1XS
ZR-75-30 NWHyfZJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF4LkOzNFMh|ryP M2fwWXNCVkeHUh?=
A673 NFXRWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHoTWM2OD1{MD61OVA4KM7:TR?= M37GeXNCVkeHUh?=
K-562 MkDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ6LkSxPFMh|ryP MmW2V2FPT0WU

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
Myc / Vinculin / pT58 Myc; 

PubMed: 25934076     


Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends).

pAkt / Akt / Skp2 / AR / pS6 / p27; 

PubMed: 24347472     


BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. 

p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; 

PubMed: 28435223     


Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot.

Bcl-2 / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 28435223     


K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. 

Cyclin D1 / Cyclin D2 ; 

PubMed: 28435223     


Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells.

mTOR / p-mTOR / p70S6K / p-p70S6K ; 

PubMed: 29581778     


Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. 

p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; 

PubMed: 21278786     


Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h. 

25934076 24347472 28435223 29581778 21278786
Immunofluorescence
SP1; 

PubMed: 26336820     


Immunofluorescence assessment of SP1 after BEZ235 treatment for 24 hrs in A673, SKNMC cells and in HFF.

p-ErbB2(Y1248); 

PubMed: 24675532     


Immunofluorescence staining of BT474.LapR cells grown in 3-D culture under different treatment conditions for a week. Scale bar indicates 50 μm.

LC3; 

PubMed: 23603977     


(A) SU-2 cells were treated with NVP-BEZ235 (10 nmol/L) for 12 h and then harvested 24 h after treatment with IR (8 Gy), and analyzed for LC3 expression (top) or the formation of autophagolysosomes by using MDC (middle) and LTR (bottom) by immunofluorescence analysis (600×magnification).

26336820 24675532 23603977
Growth inhibition assay
Cell viability (P3, U87); 

PubMed: 27542970     


IC50 doses of dactolisib for P3 (left) and U87 (right) glioma cells, generated from MTS assay. 

Cell viability (breast cancer cells); 

PubMed: 28060760     


Cell viability of breast cancer cells treated by either BEZ235 or TSA for 48h was measured by MTT assay. Each cell line was analyzed in triplicate, and a representative experiment is shown. 

Cell viability (K562, KBM7R); 

PubMed: 28435223     


(A) K562 cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (B) KBM7R cells were treated with increasing concentrations of BEZ235 for 24, 48, or 72 h and subjected to MTS assay. (C) K562 cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. (D) KBM7R cells were treated with imatinib (0–10 μM) alone or imatinib and BEZ235 (0.2 μM) for 48 h and subjected to MTS assay. Mean ± SD. n=3. *P<0.05, compared to the control group. #P<0.05, compared to the group of IM alone.

27542970 28060760 28435223
ELISA
VEGF; 

PubMed: 19671762     


NVP-BEZ235 attenuated VEGF secretion by at least 40% in U87 cells. The VEGF level in the serum-free medium was measured in triplicate and the experiment repeated at least twice to confirm results.

19671762
In vivo BEZ235 induces regression of the tumors (69%) without statistically significant effect on body weight gain. Altogether, these preliminary in vivo efficacy results show that BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in combination studies. [1]

Protocol

Kinase Assay:

[1]
- Collapse

In vitro Protein Kinase, PI3K, and mTOR Assays:

PI3Kα, β, and δ proteins are composed of the iSH2 domain of p85 NH2-terminally fused to the full-length protein p110 protein, with the exception of α that also does not contain the last 20 amino acids. PI3Kγ is produced as full-length protein deleted for its first 144 amino acids. All constructs are fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue-Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors are then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. BEZ235 are tested for their activity against PI3K using a Kinase-Glo assay. The kinase reaction is done in 384-well black plate. Each well is loaded with 50 μL of test items (in 90% DMSO) and 5 μL reaction buffer containing 10 μg/mL PI substrate (l-α-phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 150 nM of p110α, p110β, p110δ, and p110γ, respectively) are then added to it. The reaction is started by the addition of 5 μL of 1 μM ATP prepared in the reaction buffer and is incubated for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ). It is terminated by the addition of 10 μL Kinase-Glo buffer. The plates are then read in a Synergy 2 reader for luminescence detection.
Cell Research:

[2]
- Collapse
  • Cell lines: HCT116, DLD-1 and SW480 cells
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    The human CRC cell lines, HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1 (PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA wild-type) and isogenic DLD-1 PIK3CA mutant as well as wild-type cells are maintained in DMEM with 10% FBS and 1 × Penicillin/Streptomycin. Cells are plated at different initial densities (HCT116: 3 × 103 cells/well, DLD-1: 5.5 × 103 cells/well, SW480: 4.5 × 103 cells/well, DLD-1 PIK3CA mutant: 7 × 103 cells/well, and DLD-1 PIK3CA wild-type: 9 × 103 cells/well) to account for differential growth kinetics. After 16 hours, cells are incubated with increasing concentrations of BEZ235, and the drug-containing growth medium is changed every 24 hours. Cell viability is assessed 16 hours after the initial plating and 48 hours after initiation of drug treatment using the colorimetric MTS assay CellTiter 96® AQueous One Solution Cell Proliferation Assay, as per the manufacturer's instructions. Cell viability after drug treatment is normalized to that of untreated cells also grown for 48 hours. For western blot analysis, cells are plated with zero or maximum inhibitory dose (500 nM) BEZ235 for 2, 6, 24, or 48 hours.


    (Only for Reference)
Animal Research:

[1]
- Collapse
  • Animal Models: Female Harlan athymic nude mice
  • Dosages: 45 mg/kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMF 18 mg/mL warmed (38.33 mM)
DMSO 0.01 mg/mL (0.02 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
NMP+PEG300 (10+90, v+v)
For best results, use promptly after mixing. 		30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 469.55
Formula

C30H23N5O
CAS No. 915019-65-7
Storage powder
in solvent
Synonyms NVP-BEZ235
Smiles CC(C)(C#N)C1=CC=C(C=C1)N2C3=C4C=C(C=CC4=NC=C3N(C2=O)C)C5=CC6=CC=CC=C6N=C5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01856101 Terminated Drug: BEZ235 Carcinoma Transitional Cell Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Novartis February 2013 Phase 2
NCT01717898 Terminated Drug: BEZ235|Drug: Prednisone|Drug: Abiraterone acetate Castrate-resistant Prostate Cancer Charles Ryan|Novartis Pharmaceuticals|University of California San Francisco January 31 2013 Phase 1|Phase 2
NCT01756118 Unknown status Drug: BEZ235 Acute Lymphoblastic Leukemia|Leukemia Myelocytic Acute|Chronic Myelogenous Leukemia With Crisis of Blast Cells Johann Wolfgang Goethe University Hospital June 2012 Phase 1
NCT01290406 Withdrawn Drug: BEZ235 Endometrial Cancer Novartis Pharmaceuticals|Novartis March 2012 Phase 2
NCT01288092 Withdrawn Drug: BEZ235 Metastatic Breast Cancer Novartis Pharmaceuticals|Novartis March 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    With difficulties in dissolving BEZ235, How can I improve its solubility?

  • Answer:

    For in vivo study, we suggest the vehicle solution NMP/polyethylene glycol 300 (10/90, v/v). Please dissolve BEZ235 in NMP as more as possible. You can sonicate and warm it in water bath for a while. Then dilute with PEG 300.

selleck catalog

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

  • Taselisib (GDC 0032) New

    Taselisib (GDC 0032, RG7604) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with Ki of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147) New

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317 New

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • LY294002

    LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.

  • Idelalisib (CAL-101, GS-1101)

    Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR. Idelalisib also stimulates autophagy.

  • Wortmannin

    Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Wortmannin blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays. Wortmannin also inhibits PLK1 activity.

  • Buparlisib (BKM120)

    Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Buparlisib induces apoptosis. Phase 2.

  • Pictilisib (GDC-0941)

    Pictilisib (GDC-0941, RG7321) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Pictilisib (GDC-0941) induces autophagy and apoptosis. Phase 2.

  • Alpelisib (BYL719)

    Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Tags: buy Dactolisib (BEZ235) | Dactolisib (BEZ235) supplier | purchase Dactolisib (BEZ235) | Dactolisib (BEZ235) cost | Dactolisib (BEZ235) manufacturer | order Dactolisib (BEZ235) | Dactolisib (BEZ235) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID